Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

The identification of driver mutations in epidermal growth factor receptor, anaplastic
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …

Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …

Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …